Allist Pharmaceuticals, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-36
RECRUITING8
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO67%
Delay Index: of 12 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.8 months). See all sponsors →
Open Allist Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Gefitinib 250 mg NCT03787992 |
P3 | Active, not recruiting | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | 358 | 2021-09-15 (-20 mo) |
| JAB-21822 NCT05194995 |
P1/2 | Active, not recruiting | Advanced Colorectal Cancer; Small Intestinal Cancer | 48 | 2025-04-30 (+17 mo) |
| Furmonertinib NCT05466149 |
P2 | Active, not recruiting | NSCLC | 100 | 2025-06-27 (+15 mo) |
| JAB-21822 NCT05009329 |
P1/2 | Active, not recruiting | NSCLC; Solid Tumor | 315 | 2026-08 (+8 mo) |
| FORWARD NCT04853342 |
P3 | Recruiting | Non-small Cell Lung Carcinoma | 318 | 2026-12 (+36 mo) |
| JAB-21822 NCT06008288 |
P2 | Recruiting | KRAS P.G12C; Pancreatic Cancer | 88 | 2026-12-31 (+20 mo) |
| JAB-21822 NCT05288205 |
P1/2 | Recruiting | KRAS P.G12C; Non-small Cell Lung Cancer | 240 | 2027-03 (+12 mo) |
| JAB 21822 NCT05276726 |
P1/2 | Recruiting | Non-small Cell Lung Cancer | 104 | 2027-08 (+44 mo) |
| Firmonertinib Mesilate Tablets NCT06956001 |
P3 | Recruiting | EGFR; NSCLC (Advanced Non-small Cell Lung Cancer) | 300 | 2027-12 |
| FIRMOST NCT07010419 |
P3 | Recruiting | NSCLC; Adjuvant Treatment | 338 | 2028-10-31 |
| Furmonertinib Mesilate Tablets NCT06970639 |
P3 | Recruiting | NSCLC Patients With Brain Metastasis | 380 | 2029-03 |
| JAB-21822 NCT06416410 |
P3 | Recruiting | Advanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer | 392 | 2029-09-30 (+36 mo) |